SEC Form 4 · accession 0001179110-17-009094
IMMUNOGEN INC · IMGN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Joseph J Villafranca
Director
Period of report
Jun 13, 2017
Accepted (ET)
Jun 15, 2017 · 10:00 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000855654
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Share UnitF1,F3,F2 | $0.00 | Jun 13, 2017 | A | 3,000 | A | Sep 1, 2017 | — | Common Stock | 3,000 | 89,845 | D |
| Stock option (right to buy)F4 | $4.64 | Jun 13, 2017 | A | 10,000 | A | Sep 1, 2017 | Jun 13, 2027 | Common Stock | 10,000 | 10,000 | D |
Explanation of responses
- F1The deferred share units were issued pursuant to the Issuer's Compensation Policy for Non-Employee Directors and are convertible into Common Stock on a one-to-one basis.
- F2The vested deferred share units are to be settled 100% in shares of Common Stock of the Company upon the reporting person's retirement from the Board of Directors.
- F3The deferred share units vest quarterly on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date.
- F4Exercisable as to 2,500 shares on 9/1/17, 12/1/17, 3/1/18 and 6/1/18, contingent upon the individual remaining a director as of each vesting date.